OFIX

Orthofix Medical($OFIX): Major Shareholder Invests $1.23M Following 35% Stock Plunge, Contrasting with Executive Selling Pattern

05/08/2025 22:44

Orthofix Medical Inc ($OFIX), a manufacturer of orthopedic medical devices, has caught investor attention following a significant purchase by a major shareholder after a recent stock price plunge. Shareholders are closely watching to determine whether this movement signals a turnaround or indicates deeper issues. The $OFIX share price has experienced a sharp decline since early April, falling nearly 35% in about a month. Trading in the mid-$16 range until late March, the stock dropped to $12.02 by May 7, 2025. This decline occurred contrary to broader market trends, as major indices showed gains in early May. Notably, immediately following the price collapse, major shareholder Engine Capital Management, LP purchased 100,000 shares at an average of $12.31, representing a total investment of $1,231,000 on May 7. According to SEC filings, this transaction was jointly filed by several related entities that collectively own more than 10% of the company's outstanding shares. This may suggest the major shareholder sees positive value in the company at current price levels. Interestingly, this large purchase followed multiple share sales by company executives. Chief Accounting Officer Geoffrey Gillespie consistently made small sales from December 2024 through April 2025, while President Massimo Calafiore sold approximately 19,281 shares (worth about $327,376) in January 2025. Additionally, CFO Julie Andrews sold 4,655 shares ($83,278) on January 16, and CLO Jorge Cedron disposed of 3,816 shares ($50,791) on April 16. However, there were also some positive signals. President Massimo Calafiore purchased 9,914 shares at an average of $17.43, investing a total of $172,801 on March 5. This could be interpreted as an expression of confidence in the company's future at that time, though the stock continued to decline afterward. $OFIX's recent financial performance exceeded expectations. In its Q1 2025 results announced on May 6, the company reported a loss of 8 cents per share, significantly better than the 27-cent loss analysts had projected. Revenue increased by 2.7% year-over-year to $193.65 million, surpassing expectations of $191.10 million. Despite these positive results, the stock price fell sharply the day after the earnings announcement. Orthofix also announced last July that it had received 510(K) clearance from the FDA for its Fitbone Transport And Lengthening System and successfully completed its first implant. This system represents an important addition to the company's orthopedic portfolio. Market analysts maintain a positive outlook on $OFIX. The average analyst rating remains 'buy' with a median 12-month price target of $24.00, approximately 100% above the current share price. This suggests that the recent price decline may be excessive. The orthopedic medical device market continues to grow, driven by an aging population and an increase in sports-related injuries. Orthofix, specializing in spine and orthopedic solutions, is working to position itself within this growing market. Investors should monitor several key factors going forward. First, whether Engine Capital will make additional purchases or strategic interventions; second, any further buying or selling patterns among company executives; and third, whether the next quarterly results will maintain growth momentum. Additionally, the specific causes of the recent share price decline (not yet fully disclosed) will be an important observation point. At present, $OFIX stands at an interesting balance point between signals of confidence from a major shareholder and market skepticism. Whether the current share price represents an attractive entry point or signals more fundamental problems will likely become clearer in the coming months.

You can receive notifications when news is published.